药物基因组学对肝移植术后免疫抑制药物疗效的影响研究进展
摘要
移植排斥反应是肝移植术后最主要的危险因素,除非给予免疫抑制剂。不同个体之间免疫抑制剂的代谢是存在很大差异,而存在这种差异的原因很可能以药物代谢相关基因有很大关系,所以研究免疫抑制剂的药物基因组学对于提高肝移植术后药物疗效及减少不良反应的发生都有很重要的意义,同时这种方法也有助于免疫抑制剂的个体化用药。
出处
《中外医疗》
2013年第7期187-188,190,共3页
China & Foreign Medical Treatment
参考文献14
-
1Yagil Y, Yagil C. Insights into pharmacogenomics and its impact upon immuno suppressive therapy[J]. Transplant Immunol,2002,9(2--4):203-209.
-
2Hoffmeyer S, Burk O, Von Richter O,et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo[J].Proc Natl Acad Sci USA,2000,97(7):3473-3478.
-
3Domanski TL, Finta C, Halpert JR,et al. cDNA cloning and initial char- acterization of CYP3A43, a novel human cytochrome P450[J].Mol Phar- macol,2001,59(2):386-392.
-
4Kuehl P, Zhang J, Lin Y,et al.Sequence diversity in CYP3Apromoters and charac -terization of the genetic basis of polymorphic CYP3A5 ex- pression[J].Nat Genet, 2001, 27(4):383-391.
-
5Finta C, ZaphiropoulosPG. The human cytochrome P450 3Alocus. Gene evolution by capture of downstream exons[J].Gene,2000,260(1-2):13-23.
-
6Siegmund W, Ludwig K, Giessmann T,et al. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and dis- position of the probe drug talinolol [J].Clin Pharmacol Ther,2002,72(5): 572-583.
-
7Laurence BF, Aurore D, Faouzi S,et al.MDR-1C3435T polymorphism influences cyclosporine A dose requirement in liver transplant recipients [J]. Transplant -ation,2004,78(6):21.
-
8Dany A, Eric T, Isabelle E.CYP3A5and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation[J].Clinical Pharmacology &Therapeuti -cs,2004,75(5):422.
-
9Li D, Zhu JY, Gao J,et al. Polymorphisms of tumornecrosis factor-a, in- terleukin -10, cytochrome P4503A5and ABCBlin Chinese liver trans- plant patientstreated with immunosuppressant tacrolimus [J].ClinChim Acta,2007,383(8): 133.
-
10Hashida T, Masuda S, Uemoto S,et al. Pharmacokinetic and prognostic significance of intestinal MDR1 expression in recipients of living- donorliver transplantation[J].Clin Pharmacol Ther,2001,69(5):308-316.
-
1杨杰翔,肖复兴,扶世杰.骨质疏松症相关基因研究进展[J].西部医学,2009,21(5):849-850.
-
2李宝华,裘正军,钟福全,张明珍.重症胰腺炎早期手术与非手术治疗的比较研究[J].上海医学,1995,18(11):621-623. 被引量：5
-
3李玉斌,张赛,梁冰.脑室镜辅助与常规脑室腹腔分流术并发症的对比分析[J].中国内镜杂志,2011,17(3):255-258. 被引量：8
-
4陈耿,董家鸿.药物基因组学:优化器官移植受者免疫抑制治疗的新策略[J].中华器官移植杂志,2004,25(6):379-381. 被引量：1
-
5于立新,王彦斌,付绍杰,肖露露,李强,王亦斌,叶俊生.肾移植术后稳定期受者应用他克莫司的剂量及血药浓度个体差异的研究[J].中华器官移植杂志,2009,30(4):242-243.
-
6金昭,蔡卫民.他克莫司基因组学在肝移植的应用及其研究进展[J].中国临床药理学杂志,2008,24(2):165-168. 被引量：10
-
7刘静,王虎军,赵刚涛.肾移植删艮用他克莫司的药物基因组学因素分析[J].浙江临床医学,2012,14(10):1175-1178.
-
8秦新裕.青年外科医师实验研究思维与能力的培养[J].中华实验外科杂志,2009,26(6):685-686.
-
9刘龙山,王长希.他克莫司用于肾移植临床治疗的进展[J].世界临床药物,2014,35(3):134-140. 被引量：5
-
10陈耿,董家鸿.器官移植受体个体化免疫抑制策略的现状与展望[J].中华外科杂志,2006,44(3):211-214. 被引量：1
